These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31743620)

  • 1. Comparison of cumulative viraemia following treatment initiation with different antiretroviral regimens: a real-life study in Brazil.
    Pascom AR; Pinho RE; Rick F; Veras NM; Perini FB; Meireles MV; Pereira GF; Benzaken AS; Avelino-Silva VI
    J Int AIDS Soc; 2019 Nov; 22(11):e25397. PubMed ID: 31743620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir.
    Meireles MV; Pascom ARP; Duarte EC; McFarland W
    AIDS; 2019 Aug; 33(10):1663-1668. PubMed ID: 31082860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil.
    Pascom ARP; Fonseca FF; Pinho RGG; Perini FB; Pereira G; Avelino-Silva VI
    Int J STD AIDS; 2020 Aug; 31(9):903-910. PubMed ID: 32702281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
    Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
    AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
    Dorward J; Sookrajh Y; Khubone T; van der Molen J; Govender R; Phakathi S; Lewis L; Bottomley C; Maraj M; Lessells RJ; Naidoo K; Butler CC; Van Heerden R; Garrett N
    Lancet HIV; 2023 May; 10(5):e284-e294. PubMed ID: 37001536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study.
    Kamara DA; Smith C; Ryom L; Reiss P; Rickenbach M; Phillips A; Mocroft A; De Wit S; Law M; Monforte AD; Dabis F; Pradier C; Lundgren JD; Sabin C
    Antivir Ther; 2016; 21(6):495-506. PubMed ID: 27114439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: A Swedish observational study.
    Brattgård H; Björkman P; Nowak P; Treutiger CJ; Gisslén M; Elvstam O
    PLoS One; 2022; 17(5):e0268540. PubMed ID: 35580115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV treatment outcomes among people with initiation CD4 counts >500 cells/µL after implementation of Treat All in South African public clinics: a retrospective cohort study.
    Dorward J; Sookrajh Y; Gate K; Khubone T; Mtshaka N; Mlisana K; Ngobese H; Yende-Zuma N; Garrett N
    J Int AIDS Soc; 2020 Apr; 23(4):e25479. PubMed ID: 32319203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
    Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
    Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Super learner analysis of real-time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to non-differentiated care approaches for persons living with HIV in rural Uganda.
    Benitez AE; Musinguzi N; Bangsberg DR; Bwana MB; Muzoora C; Hunt PW; Martin JN; Haberer JE; Petersen ML
    J Int AIDS Soc; 2020 Mar; 23(3):e25467. PubMed ID: 32202067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
    Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
    Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
    Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
    Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early HIV viral suppression associated with subsequent 12-month treatment success among people living with HIV in South Africa.
    Violette LR; Thomas KK; Dorward J; Quame-Amaglo J; Garrett N; Drain PK
    HIV Med; 2024 Jun; 25(6):759-765. PubMed ID: 38488308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.